MuGard, a FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis and stomatitis, is now being introduced to Centers of Excellence, Key Opinion Leaders, cancer research centers and selected physicians in the United States.
Access Pharmaceuticals, Inc. (OTC Bulletin Board:ACCP.ob - News), a biopharmaceutical company specializing in products for cancer and supportive care, today announced its e-marketing partner, iMedicor (OTC Bulletin Board:VMCI.ob - News) commenced the initial phase of a multi-channel marketing program for MuGard.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.